High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy

BACKGROUND AND AIM: Recently, Siglec-15 has been proved as a novel immune suppressor and a potential target for normalization cancer immunotherapy, which is non-redundant to the well-known PD-L1/PD-1 pathway. Herein, anti-Siglec-15 mAb, a monoclonal antibody (mAb) with a high affinity against Siglec...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Fei, Wang, Na, Li, Jiangwei, He, Luanying, Yang, Zhao, Lu, Jiandong, Xiong, Guoliang, Yu, Changyuan, Wang, Shihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Whioce Publishing Pte. Ltd. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710358/
https://www.ncbi.nlm.nih.gov/pubmed/34988324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710358/
https://www.ncbi.nlm.nih.gov/pubmed/34988324

Ejemplares similares